Table 3.
Mean Plasma Markers of Oxidative Stress over Study Period, by Treatment Group
| Placebo (N = 26) |
600 mg Coenzyme Q10 (N = 18) |
1200 mg Coenzyme Q10 (N = 21) |
|
|---|---|---|---|
| F2-isoprostanes, pg/ml | |||
| Baseline | 49.3 (40.6, 58.0) | 45.6 (35.1, 56.1) | 62.4 (43.5, 81.3) |
| 1 month | 54.0 (44.8, 63.2) | 47.1 (38.7, 55.6) | 48.5 (36.8, 60.3) |
| 2 months | 50.4 (41.1, 59.7) | 42.1 (32.6, 51.6) | 51.9 (37.2, 66.7) |
| 4 months | 45.1 (36.6, 53.6) | 39.2 (30.9, 47.6) | 47.5 (33.2, 61.8) |
| p-valuea | Reference | 0.34 | 0.002 |
| Isofurans, pg/ml | |||
| Baseline | 64.8 (56.4, 73.1) | 68.1 (60.1, 76.2) | 94.2 (77.7, 110) |
| 1 month | 86.2 (62.5, 110) | 84.5 (67.5, 102) | 73.2 (57.4, 88.9) |
| 2 months | 75.6 (62.5, 86.7) | 90.0 (57.9, 122) | 115 (74.8, 155) |
| 4 months | 69.8 (60.0, 79.6) | 73.5 (62.9, 84.0) | 82.8 (66.7, 98.9) |
| p-valuea | Reference | 0.71 | 0.07 |
Note: Results reported are from the primary intention-to-treat analysis. Values are least squares means (95% confidence interval), adjusted for age, sex, race, and etiology of end-stage renal disease.
a
p-value for comparison of average treatment effect from generalized estimating equation model, adjusted for age, sex, race, etiology of end stage renal disease, and baseline measurements; reference group: placebo. Outcome measurements log transformed prior to analysis.